a Previous studies have suggested that treatment with antagonists or partial agonists of nicotinic acetylcholine receptors containing the b2-subunit (b2* nAChRs) results in antidepressant-like effects. In this study, we tested three novel compounds with different affinity and functional efficacy at a4b2* nAChRs, which were synthesized as part of nAChR discovery projects at Pfizer, in the tailsuspension, forced-swim, and novelty-suppressed feeding tests of antidepressant efficacy. All compounds tested reduced immobility in the forced-swim test and one of the compounds also reduced immobility in the tail-suspension test. All the compounds appeared to affect food intake on their own, with two compounds reducing feeding significantly in the home cage, precluding a clear interpretation of the results in the novelty-suppressed feeding test. None of the compounds altered locomotor activity at the doses and time points used here. Therefore, a subset of these compounds has pharmacological and behavioral properties that demonstrate the potential of nicotinic compounds as a treatment of mood disorders. Further development of nicotinic-based antidepressants should focus on increasing nAChR subtype selectivity to obtain consistent antidepressant properties with an acceptable side-effect profile.
In this study, we tested three novel compounds with different affinity and functional efficacy at a4b2* nAChRs, which were synthesized as part of nAChR discovery projects at Pfizer, in the tailsuspension, forced-swim, and novelty-suppressed feeding tests of antidepressant efficacy. All compounds tested reduced immobility in the forced-swim test and one of the compounds also reduced immobility in the tail-suspension test. All the compounds appeared to affect food intake on their own, with two compounds reducing feeding significantly in the home cage, precluding a clear interpretation of the results in the novelty-suppressed feeding test. None of the compounds altered locomotor activity at the doses and time points used here. Therefore, a subset of these compounds has pharmacological and behavioral properties that demonstrate the potential of nicotinic compounds as a treatment of mood disorders. Further development of nicotinic-based antidepressants should focus on increasing nAChR subtype selectivity to obtain consistent antidepressant properties with an acceptable side-effect profile. 
Introduction
Individuals with major depressive disorder are twice as likely to smoke as the general population, demonstrating that there is significant comorbidity between smoking and depression-related disorders, and smoking cessation can exacerbate symptoms of depression (Glassman et al., 1990) . Conversely, the use of the nicotine patch can reduce symptoms of depression in people who do not smoke (Salin-Pascual et al., 1995) , and animal studies suggest that chronic nicotine administration can result in antidepressant-like phenotypes in various models of antidepressant effects (Semba et al., 1998; Djuric et al., 1999; Tizabi et al., 1999) . This has led to the idea that smokers may use the nicotine in tobacco to self-medicate depressive symptoms.
Heightened cholinergic tone, after administration of an acetylcholinesterase inhibitor to humans, can result in increased symptoms of depression (Janowsky et al., 1972 (Janowsky et al., , 1974 and an increased sensitivity to cholinergic agents has been reported in depressed patients (reviewed in Janowsky et al., 1994) . It was initially believed that heightened cholinergic tone was acting mainly through muscarinic acetylcholine receptors, and muscarinic blockers can show antidepressant-like effects (Furey and Drevets, 2006) ; however, an increased cholinergic tone will also affect the function of nicotinic acetylcholine receptors (nAChRs), and a growing body of studies suggests that modulation of nAChR function is associated with antidepressant-like effects (Picciotto et al., 2008; Picciotto, 2009, 2010) . The idea that increased acetylcholine (ACh) signaling in the brain may contribute to depressive symptoms seemed at odds with the finding that chronic nicotine administration can also be an antidepressant. These observations can be reconciled when taking into account that nicotine initially activates, but subsequently desensitizes nAChRs, which leads to a persistent decrease in endogenous cholinergic signaling after chronic nicotine exposure (Quick and Lester, 2002; Picciotto et al., 2008; Mineur and Picciotto, 2010) . Thus, limiting ACh-induced nAChR activation may be expected to have antidepressant-like properties. We previously showed that the antagonist mecamylamine, a noncompetitive, nonselective nAChR channel blocker, has antidepressantlike effects in several animal models of antidepressant effects (Caldarone et al., 2004; Rabenstein et al., 2006) . Recent clinical studies have confirmed the antidepressant potential of mecamylamine (Dunbar et al., 2007; George et al., 2008) and of an enantiomer, ( + )-mecamylamine (Dunbar, 2009 ), in patients with major depression previously unresponsive to a selective serotonin reuptake inhibitor.
Experiments using knockout mice (Rabenstein et al., 2006) and pharmacological studies with selective nicotinic compounds (Mineur et al., 2007c (Mineur et al., , 2009a suggest that a reduced activity at high-affinity a4b2* nAChRs mediates the antidepressant-like properties of nicotinic antagonists and partial agonists (* denotes potential additional subunits in vivo; when subtypes are tested in vitro with defined subunits no * is used). Varenicline is an a4b2 nAChR partial agonist (Coe et al., 2005a; Rollema et al., 2007a ) that also induces antidepressant-like behavior in the forced-swim test in two different mouse strains and augments the effect of the selective serotonin reuptake inhibitor sertraline in the forced-swim test in CD-1 mice . Derivatives of another nAChR partial agonist, cytisine, have also been shown to exhibit antidepressant-like properties (Mineur et al., 2009a) . Here, we examined the effects of three compounds that were identified as high-affinity/low-efficacy a4b2 nAChR partial agonists, in mouse models of antidepressant effects to evaluate their potential for clinical development.
Methods

Subjects
C57BL/6J male mice (240 mice, 10-12 weeks of age) were purchased from Jackson Laboratory (Bar Harbor, Maine, USA). Upon arrival, subjects were split into groups of five mice, and were randomly assigned to a specific treatment group (n = 10 for all groups). Mice were allowed to acclimate for at least 1 week before beginning experiments. Three days before the experiments, mice were marked with a permanent marker at the base of their tail and subsequently weighed. This was repeated each week. All in-vivo procedures were conducted in compliance with a protocol approved by the Yale Animal Care and Use Committee.
Behavioral assays
As previous studies have demonstrated that subjecting a single cohort of C57BL/6J mice to a battery of tests of antidepressant efficacy yields similar results to performing each test in a separate cohort of mice (Rabenstein et al., 2006; Mineur et al., 2007b Mineur et al., , 2007c and reduces the number of subjects necessary for behavioral testing, the same mice were used in a battery of behavioral tests. Each individual mouse received the same compound at a single concentration in each test (i.e. if a mouse received compound A at 1 mg/kg, that subject received one injection before tail-suspension testing, one injection before forced-swim testing, and then one injection daily for 15 days followed by novelty-suppressed feeding testing). The least stressful test was performed first, as has been suggested for behavioral phenotyping (Crawley et al., 1997; Crawley, 2008) . The schedule of behavioral testing was as follows: day 1: tail-suspension test; day 8: forcedswim test 1; day 23: novelty-suppressed feeding test; and day 26: locomotor activity (20 min). Both the tailsuspension and the forced-swim tests are sensitive to acute antidepressant administration (Cryan and Holmes, 2005) , whereas the novelty-suppressed feeding test is only sensitive to chronic treatment with antidepressants (Dulawa and Hen, 2005) .
For all procedures, mice were transferred to the testing room at least 30 min before the beginning of testing. Experimenters were blind to treatment. Mice were only returned to the colony room once all subjects had completed the day's testing. Four cohorts of 60 mice were tested in these studies.
Tail-suspension test
For tail-suspension testing, mice were gently suspended by the tail and scored for the time spent immobile over the 6-min test as described previously (Mineur et al., 2007b) . Immobility was defined as no movement except for respiration. After completion of the test, mice were returned to a holding cage until all cage mates were tested.
Forced-swim test
Mice were placed in clear glass beakers filled with 15-cm water (approximately 251C) for 15 min with care taken not to put the nose of the mouse below the water level when initially placed in the container (Mineur et al., 2007c (Mineur et al., , 2009b . Any mice that appeared to be in distress were immediately removed from the water. Mice were scored for time spent immobile (immobility was defined as a minimal amount of movement made by the mouse to stay afloat). After testing, each mouse was placed in a heated holding cage (30-351C) with bedding covered by a paper towel and then returned to the holding room.
Novelty-suppressed feeding test
Each compound was injected once daily for 15 days (each mouse received only one dose of a compound). After treatment, mice were weighed and food was removed from the cage. Twenty-four hours later, mice were transferred to the testing room, weighed again, placed in a clean holding cage, and were allowed to habituate for at least 30 min. Mice were then placed in a corner of the testing apparatus, consisting of a clear Plexiglas enclosure (40 Â 40 Â 17 cm), with a lid and 2 cm of corncob bedding. A small piece of chow (about 0.5 cm in diameter) was placed in the center of the arena on a piece of white circular filter paper (9.5 cm in diameter). After initiation of testing, the time to the first feeding event was measured. Upon initiation of feeding behavior, the mouse was removed from the testing area and placed alone for 5 min in its original home cage with a weighed piece of lab chow. After 5 min, the lab chow pellet was weighed again to measure home cage food consumption. Once all cage mates were tested, mice were returned to their home cage.
treatment, for 20 min. Each subject was placed in a clean transparent rat cage (48 Â 22 Â 18 cm) and locomotor activity was recorded as beam breaks using the Optomax system (Columbus instruments, Columbus, Ohio, USA). Subjects were returned to their home cage at the end of the session.
Drugs
CP-360288 (3-bromocytisine), CP-601927, and CP-601932 are a4b2 nAChR partial agonists identified at Pfizer as part of drug discovery programs targeting nAChR partial agonists for smoking cessation (Coe et al., 2005a (Coe et al., , 2005b Rollema et al., 2007b) . Details of the synthesis, preclinical pharmacology, and pharmacokinetics of these compounds are reported elsewhere (Coe et al., 2005b Shaffer et al., 2009 Shaffer et al., , 2010 Chatterjee et al., 2010) . In-vitro binding affinities and relative agonist efficacies at a4b2 and a3b4 nAChR subtypes are described in Table 1 . We focused on these two receptor subtypes because a4b2* nAChRs are critical for the antidepressant-like properties of nicotinic antagonists (Caldarone et al., 2004; Rabenstein et al., 2006; Mineur et al., 2007c) and because a3b4 nAChRs can contribute to increased anxiety-like behavior and decrease feeding (Salas et al., 2004; Mineur et al., 2007a) , which are potential confounding factors for the paradigms used in this study.
Doses were selected based both on drug affinities for nAChR subtypes and on previous results obtained with varenicline and cytisine (Mineur et al., 2007c (Mineur et al., , 2009b , whereas upper dose limits were determined by observed adverse effects, such as arched back or decreased activity in the home cage. All compounds were dosed intraperitoneally in a volume of 10 ml/kg in phosphate-buffered saline (saline) and doses are expressed as the active base.
CP-601927 and CP-601932 were dosed at 0.25, 0.5, 0.75, 1.0, and 1.5 mg/kg. As initial high doses of 3-bromocytisine significantly altered motility of mice, this compound was administered at 0.075, 0.125, 0.25, 0.75, and 1.0 mg/kg. Fluoxetine was purchased from Spectrum Chemicals (New Brunswick, New Jersey, USA) and used at 10 mg/kg as a positive control following the same regimen of testing as the nicotinic compounds. Saline or drug was injected intraperitoneally 30 min before the tail-suspension test or the forced-swim test, and the two tests were separated by 1 week. After the forced-swim test, saline or drug was injected once daily (between 09:00 and 11:00 h) for 15 days, after which mice were tested in the noveltysuppressed feeding paradigm. Novelty-suppressed feeding was performed in the morning before the usual daily injection to avoid any acute effects of the drugs. For each test, experiments were performed under similar conditions and in parallel with fluoxetine (10 mg/kg, intraperitoneally) and varenicline (1.5 mg/kg) as positive controls ).
Statistical analyses
Data were analyzed using one-way analyses of variance with 'dose' as a between-subject factor. When relevant, post-hoc analyses were performed by t-tests with TukeyKramer corrections for multiple comparisons. For analysis of locomotor activity data, we performed a repeatedmeasure of analyses of variance with '2-min time bin' as a within-subject factor, and 'treatment' as a betweensubject factor. A P value of less than 0.05 was considered significant.
Results
Properties of test compounds Table 1 summarizes binding affinities and intrinsic activities of 3-bromocytisine, CP-601927, and CP-601932 at a4b2 and a3b4 nAChRs compared with nicotine, cytisine, and varenicline. The test compounds have high affinity and relatively low efficacy for a4b2 nAChRs, whereas potencies Table 1 Binding affinity (Ki , nmol/l ± standard deviation, n = 4-13), agonist efficacy, and structures of nicotine and a4b2 nAChR partial agonists a4b2 nAChRs partial agonists as antidepressants Mineur et al. 293 and efficacies at a3b4 nAChRs vary. All compounds used here had low-binding affinity for a1-containing (Ki Z 0.5 mmol/l) and a7-containing nAChRs (Ki > 1 mmol/l), except for 3-bromocytisine, which is a full agonist at a7 nAChRs with a Ki value of 29 nmol/l. Finally, all compounds had good brain penetration after systemic administration Rollema et al., 2010) . At the highest doses used for testing of antidepressant-like efficacy, none of the test compounds altered locomotor activity, indicating that results were not confounded by stimulant effects of these compounds [F(2,18) = 0.32, P = 0.99; Fig. 1 ].
Tail suspension 3-Bromocytisine or CP-601927 had no overall effect in the tail-suspension test [F(4,44) = 0.40, not significant (NS) and F(4,40) = 1.96, NS, respectively, Figs 2a and b] . However, CP-601932 induced an overall effect on the reduction of time spent immobile [F(4,45) = 5.38, P < 0.02; Fig. 2c ]. Post-hoc analyses indicated that compared with the control group, only the 1.5-mg/kg dose of CP-601932 was significantly different from saline in reducing time spent immobile (P < 0.001), whereas other doses resulted only in nonsignificant effects on immobility. As positive controls, both varenicline (1.5 mg/kg) and fluoxetine (10 mg/kg) significantly decreased immobility [F(1,18) = 4.72, P < 0.05 and F(1,18) = 50.89, P < 0.001, respectively].
Forced-swim test 3-Bromocytisine showed an overall effect across doses in the forced-swim test [F(4,34) = 7.44, P < 0.001, Fig. 3a ].
In comparison with the control group, post-hoc analyses revealed a significant reduction in the time spent immobile at 0.075 mg/kg (P < 0.001), 0.125 mg/kg (P < 0.001), and 1 mg/kg (P < 0.001), whereas the decrease in immobility time at 0.25 mg/kg did not reach statistical significance (P = 0.093).
CP-601927 had a significant overall treatment effect to reduce time spent immobile [F(4,44) = 12.6, P < 0.001; Fig. 3b ] in the forced-swim test. Post-hoc analyses indicated that compared with the control group, CP-601927 significantly reduced the time spent immobile (P < 0.001) for all doses tested compared with the saline-treated subjects.
CP-601932 caused an overall reduction in the time spent immobile in the forced-swim test [F(4,44) = 25.63, P < 0.001; Fig. 3b ]. Post-hoc analyses indicated that all doses tested significantly reduced the time spent immobile (P < 0.001) compared with the control group; however, the 1-mg/kg dose showed a smaller response than the other doses (0.75 vs. 1 mg/kg: P < 0.001; 1 vs. 1.5 mg/kg: P < 0.001).
As positive controls, both varenicline (1.5 mg/kg) and fluoxetine (10 mg/kg) significantly decreased immobility [F(1,17) = 141.7, P < 0.001 and F(1,17) = 6.7, P = 0.01, respectively].
Novelty-suppressed feeding test
3-Bromocytisine caused no overall reduction in the time to first feeding episode in the open field [F(5,31) = 1.1, NS; Fig. 4a ]. This compound was also found to reduce the food intake in the home cage [F(5,31) = 10.23, P < 0.001; Fig.4b ].
CP-601927 treatment caused an overall increase in the time to first feeding episode in the open field [F(4,39) = 4.86, P < 0.005; Fig. 4c ] in the novelty-suppressed feeding test, although it did not reduce food intake overall in the home cage [F(4,39) = 1.05, NS; Fig. 4d ]. Post-hoc analyses showed that 1.0 and 1.5 mg/kg significantly increased the time to first feed (P < 0.01) compared with the control group, mainly because most subjects did not eat during the test.
CP-601932 produced an overall increase in the time to first feeding episode in the open field [F(4,44) = 8.46, P < 0.001; Fig. 4e ], while reducing food intake in the home cage [F(4,44) = 5.71, P < 0.001; Fig. 4f ]. Post-hoc analyses showed that every dose significantly increased the time to the first feeding episode (P < 0.001) compared with the control group, but subjects did not eat at all after receiving most doses.
Fluoxetine significantly decreased the time to first feeding episode [F(1,19) = 7.79, P < 0.01], whereas varenicline did not induce the same effects (F < 1), and caused a significant decrease in food intake in the home cage [F(1,17) = 4.78, P < 0.05].
Discussion
The current set of studies investigated the antidepressant-like effects of three novel a4b2 nAChR partial agonists: a bromoderivative of cytisine, 3-bromocytisine, and the enantiomeric pair, CP-601927 and CP-601932, which have been in development as smoking cessation aids.
3-Bromocytisine demonstrates subnanomolar high-affinity binding for a4b2 nAChRs (Ki = 0.2 nmol/l), as well as for a3b4 nAChRs (Ki = 3.6 nmol/l), which are highly expressed in the autonomic ganglia. Potentially due to high in-vivo potency, this compound was not well tolerated at doses of 1 mg/kg and above. Above 1 mg/kg 3-bromocytisine doses caused adverse effects in mice, including abnormal movements. None of the test doses of 3-bromocytisine induced an antidepressant-like effect in the tail-suspension test, but, in agreement with its high potency, very low doses of 3-bromocytisine decreased immobility in the forced-swim test. Finally, although chronic treatment with classical antidepressants generally reduces the time to first feed in an open field (Dulawa and Hen, 2005) , 3-bromocytisine was ineffective in decreasing latency to feed in the novelty-suppressed feeding test. However, 3-bromocytisine did not induce any obvious signs of discomfort in mice at any of the doses tested (1 mg/kg and below). Mice treated with 3-bromocytisine showed reduced home cage food intake. This is consistent with previous studies of nicotinic drugs, as nicotinic agents, including cytisine, decreased food intake (Hughes and Hatsukami, 1997; Filozof et al., 2004) . A decrease in appetite would confound any interpretation of changes seen in the novelty-suppressed feeding test. In addition, the high affinity of the compound for a3b4 nAChRs could contribute to an anxiogenic effect of this compound (Salas et al., 2003) .
The discrepancy between the results of the tail-suspension and the forced-swim tests was not anticipated, as performance in both tests is sensitive to treatment with currently used antidepressants including fluoxetine. The origin of these discrepancies is unknown and is also not consistent with pK-related exposure differences between the models, as time points are virtually identical. It is conceivable that each model is responsive to distinct pharmacological properties of antidepressant drugs that are not well understood. In addition, other peripheral a4b2 nAChRs partial agonists as antidepressants Mineur et al. 295 effects (including vasoconstriction and hypothermia) may be confounds in the different outcomes measured here. Overall, the mixed effects observed across the different behavioral tests performed here, along with the poorly tolerated effects at higher doses, makes 3-bromocytisine unsuitable as a lead compound for developing a treatment of mood disorders.
Although 3-bromocytisine showed some antidepressant-like properties in this study, peripheral administration of the 5-bromo analog, 5-bromocytisine, that has comparable binding affinity for the a4b2 nAChR (Ki = 0.3 nmol/l), but lower agonist efficacy (17%) compared with 3-bromocytisine, did not induce significant effects in tests of antidepressant efficacy when administered peripherally. This was most likely due to poor brain penetration, as central administration resulted in a decreased immobility in the forced-swim test (Mineur et al., 2009a) . It is also possible that lower efficacy at a4b2 nAChRs contributed to the difference in response to the 5-bromo compared with the 3-bromo analog .
Compared with cytisine, another nAChR partial agonist previously shown to induce significant antidepressantlike effects in mice (Mineur et al., 2007b; Rollema et al., 2009 ), CP-601927, binds with lower affinity to a4b2 nAChRs and also has lower agonist efficacy (Table 1) . Thus, CP-601927 could decrease cholinergic signaling as a result of its reduced efficacy or by desensitization of a4b2* nAChRs. In the tail-suspension test, there was an observable decrease in immobility, with a peak at 0.75 mg/kg, although none of the doses tested induced a significant difference. In contrast, treatment with CP-601927 strongly decreased time spent immobile in the forced-swim test at all doses tested. The discrepancy in effects of CP-601927 in the two tests may be related to underlying differences in the two paradigms described for 3-bromocytisine above. In addition, although the compounds used here have varying affinity for nAChRs, it is difficult to relate these affinities to their antidepressant-like effects without more precise data on whether the compounds have differential penetration into the brain. However, it is also worth noting that the experimental design involved four different concentrations for each compound, along with saline and fluoxetine, which resulted in stringent statistical corrections for multiple group comparisons. Thus, although the effects of CP-601927 were smaller in the tail-suspension test compared with those observed in the forced-swim test, there was a nonsignificant but 1.5 * * * * * * * * observable effect on immobility. As with 3-bromocytisine, the effect of CP-601927 on novelty-suppressed feeding seems to be confounded by effects of the compound on home cage food intake. The ability of nicotinic agents to decrease food intake may have some value in drug development, as most classical antidepressants used currently induce weight gain (Ginsberg, 2009) . It is worth noting, however, that the decrease in home cage feeding observed with CP-601927 was not closely correlated with the decreased time to the first feeding episode in the open field, indicating that other factors may also be involved in the effects of nicotinic compounds on food intake and performance in the novelty-suppressed feeding task. For instance, acute nicotine treatment decreases open arm time in the elevated plus maze and the center of an open field, two tests correlated with anxiety-like behavior Tucci et al., 2002) , and previous studies indicate that acute injection of a nicotinic partial agonist increases time spent in the dark compartment in the light/dark test in mice (Mineur et al., 2007c) . Thus, one possibility is that this compound may increase the time for the mice to reach the center of the open field and eat through a similar mechanism to other nicotinic agents that are effective in models of anxietylike behavior.
CP-601932 has minimal agonist efficacy at a4b2 nAChRs as measured by in-vitro physiological assays and is therefore a functional antagonist with lower binding affinity for a4b2 nAChRs compared with the other compounds tested in this study. This compound also has equivalent affinity for a4b2 and a3b4 nAChRs (21 nmol/l), with significant efficacy (30%) at the a3b4 subtype; thus, this compound may affect both nAChR subtypes (Chatterjee et al., 2010) . In the tail-suspension test, CP-601932 dose dependently decreased immobility and this reached significance at the highest dose tested. Similar effects of CP-601932 were observed in the forced-swim test, but significance was reached at the lowest concentration tested. Finally, the results in the novelty-suppressed feeding test were inconclusive, as has been discussed for the two other compounds tested in this study, because CP-601932 dose dependently decreased feeding in the home cage, and was negatively correlated with the time to first feed in the open field. This strongly suggests that decreased appetite was a primary factor in the effects of CP-601932 on behavior in this paradigm.
In conclusion, an emerging body of data indicates that decreasing signaling at nAChRs can induce antidepressant-like responses in mouse models of antidepressant effects. The current studies characterize novel nicotinic compounds with efficacy in the forced-swim test. Blockade of a4b2* nAChRs can result in antidepressant-like effects; but reducing cholinergic signaling by a4b2* nAChRs using partial agonists that compete with endogenous ACh signaling may be more desirable than complete blockade of these receptors. It is not yet possible to determine how much of a decrease in cholinergic tone is necessary to achieve an antidepressant-like response, but it is very likely that this depends on the degree of cholinergic activity present during the behavioral evaluation and the complement of cholinergic receptors available for signaling in the particular individual tested. Although it is difficult to quantify the effects of nicotinic compounds across animal models that may have differential activation of the cholinergic system, nicotinic agonists seem to be less effective than antagonists of high-affinity nAChR receptors in mouse models of antidepressant effects ). In addition, complete blockade of nAChRs may lead to more, or different, side-effects than partial agonism. All test compounds display high affinity for a4b2 nAChRs and consistency in performance in the forced-swim test, but show varying effects at a3b4 nAChRs and inconsistency in tolerability at higher doses. Thus, subtype selectivity for the a4b2 class of nAChRs should also be a key element in the development of nicotinic compounds to be used for treatment of depression, as modulation of other nAChR subtypes may result in increased anxiety and perturbation of feeding (Salas et al., 2003; Mineur et al., 2007a) . Thus, the challenge for further development of nicotinic-based antidepressants will be to increase nicotinic receptor specificity along with a moderate decrease in the activity of endogenous cholinergic activation of a4b2* nAChRs to obtain consistent antidepressant properties with limited side-effects.
